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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYOver the last several years, mesenchymal stromal cells (MSCs) have been isolated from different tissues following a variety of
different procedures. Here, we comparatively assess the ex vivo and in vivo properties of MSCs isolated from either adipose tissue
or bone marrow by different purification protocols. After MSC transplantation into a mouse model of hindlimb ischemia, clinical
and histological analysis revealed that bone marrow MSCs purified on adhesive substrates exerted the best therapeutic activity, pre-
serving tissue viability and promoting formation of new arterioles without directly transdifferentiating into vascular cells. In keeping
with these observations, these cells abundantly expressed cytokines involved in vessel maturation and cell retention. These findings
indicate that the choice of MSC source and purification protocol is critical in determining the therapeutic potential of these cells and
warrant the standardization of an optimal MSC isolation procedure in order to select the best conditions to move forward to more
effective clinical experimentation.INTRODUCTION
Mesenchymal stromal cells (MSCs) are defined as multi-
potent, self-renewing cells residing in several tissues,
including the bone marrow, adipose tissue, umbilical cord
blood, and placenta (Pittenger et al., 1999). These cells
are defined as multipotent, as they are capable of gener-
ating different mesenchymal cell types, traditionally adi-
pocytes, chondrocytes, and osteocytes, but also smooth
muscle cells and cardiomyocytes (Makino et al., 1999; Pit-
tenger et al., 1999).MSCs have been at the forefront of clin-
ical research for the therapy of cardiovascular disorders for
many years. In particular, cardiac and peripheral ischemia
is a leading cause of morbidity and mortality in our aging
society and suffers from a lack of curative therapies (Ten-
dera et al., 2011). In this setting, MSC transplantation has
been proposed as an innovative therapy for no-option
ischemic patients. Originally, the therapeutic potential of
these cells was thought to arise through their putative ca-
pacity to transdifferentiate, thereby directly contributing
to vasculogenesis and tissue regeneration (Quevedo et al.,
2009). This attractive hypothesis led to the prompt,
perhaps immature transition of the results obtained in an-
imal models to the clinics, with the ambitious goal to
regenerate ischemic tissues (Hare et al., 2009; Tateishi-
Yuyama et al., 2002). However, MSC plasticity has been
later harshly questioned (Noiseux et al., 2006), and the
therapeutic potential of these cells is currently considered
to derive from the secretion of a variety of growth factors332 Stem Cell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authand cytokines exerting a paracrine, protective effect on
ischemic cells (Gnecchi et al., 2012).
Despite the common definition of MSCs and the
modest but real therapeutic effect exerted by these
cells in various experimental and clinical settings,
there is no universal agreement on the optimal source
and method for MSC isolation and culture (Soleimani
and Nadri, 2009; Sung et al., 2008; Yamamoto et al.,
2007). This importantly limits the possible comparison
of the observed results in terms of MSC characteriza-
tion and therapeutic activity. Most of the studies that
compared different MSC types are based on the analysis
of surface markers, multipotency, and angiogenic assays
ex vivo (Lee et al., 2004; Peng et al., 2008). A few
studies also compared MSC activity in vivo, in animal
models of cardiac and limb ischemia, but they consid-
ered either different tissue sources (van der Bogt
et al., 2009) or different purification methods (Seeger
et al., 2007) and never the combination of the two pa-
rameters. Additional relevant variables in these studies
are the species from which MSCs were isolated and
the specific animal model used to ascertain their thera-
peutic properties. This again prevents the direct com-
parison of most of the existing studies and warrants
the prospective characterization of MSCs derived from
various tissues and purified according to different puri-
fication protocols.
Here, we provide evidence that murine MSCs, harvested
from either adipose tissue or bone marrow and followingors
different purification procedures, behave differently and,
most importantly, exhibit different therapeutic potential
in a mouse model of critical limb ischemia (CLI). This un-
derlines the need to adopt optimal and standardized
methods for MSC processing in future preclinical and clin-
ical trials.
RESULTS
MSCs Isolated fromDifferent Sources and according to
Different Procedures Show a Common Phenotype
To identify the optimal population of MSCs to treat
hindlimb ischemia, cells were purified from either the
adipose tissue or the bone marrow of mice using three
different protocols. Adipose tissue (AT) MSCs were iso-
lated by tissue digestion followed by centrifugation,
while bone marrow (BM)-derived MSCs were obtained
by either frequent medium changes (BM-MSCs) or
immunodepletion (iBM-MSCs) (Figure 1A). In all
three cases, the first MSC colonies appeared after a
few days and cells were cultured until they reached
80% confluence (within 10 days for AT-MSCs and
6 weeks for both types of BM-derived cells). When
assessing their proliferative potential, iBM-MSCs ap-
peared to grow significantly faster than the other
populations (Figure 1B). When seeded at a low number,
all three MSC cell types formed a similar number of
colonies, confirming their clonogenic potential (Figures
1C and 1D). Despite their high proliferative capacity,
MSCs did not become immortal but started to
express the senescence-associated b-galactosidase (SA-
bgal) marker at passage 12 (Figure S1A available online)
and stopped multiplying after an additional three to six
passages.
Regardless of their different origin and isolation protocol,
the three cell populations exhibited a very similar marker
profile. They abundantly expressed the MSC-defining
CD44, CD105, CD29, and CD90 markers, whereas they
scored negative for endothelial (CD31), myeloid (CD11b,
GR-1), or hematopoietic (CD45 and CD34) antigens (Box-
all and Jones, 2012). Low levels of expression were also
found for SCA-1, c-KIT, TIE-2, CXCR4, and TER-119 (Fig-
ures 1E and S1B; Table S1).
Finally, AT-MSCs, iBM-MSCs, and BM-MSCs were probed
for their capacity to differentiate into adipocytes, chondro-
cytes, and osteocytes. Adipogenic medium induced the
appearance of lipid vacuoles, positive to oil red staining;
chondrogenic medium forced the cells to accumulate al-
cian blue-positive proteoglycans; and osteogenic medium
dramatically induced accumulation of intracellular cal-
cium deposits, reactive to Alizarin staining (Figure 1F).
These results confirm the multipotency of the three MSC
populations.Stem CTransplantation of AT-MSCs, iBM-MSCs, and BM-
MSCs Markedly Reduces Severe Hindlimb Ischemia
We assessed MSC therapeutic potential in a mouse
model of hindlimb ischemia induced by removal of
the entire femoral artery. The day following surgery,
the animals received 2 3 105 cells (or medium as con-
trol) in the limb homolateral to ischemia (Figure 2A).
Clinical follow-up over 3 weeks showed a significant
improvement in the group injected with iBM-MSCs,
but the most significant improvement was seen in the
group injected with BM-MSCs (Figure 2B). Histological
analysis of muscle sections at day 21 showed extensive
necrosis, adipose substitution, and marked infiltration
by inflammatory cells in control animals. In contrast,
the muscles injected with any MSC population showed
a statistically significant reduction of the inflammatory
infiltrate (Figures 2C and 2D), associated with a smaller
lesion area (Figures 2C and 2E). In addition, the number
of regenerating fibers, characterized by central nuclei,
was significantly higher in animals treated with cells of
BM origin, in particular in the case of BM-MSCs (Figures
2C and 2F). Thus, postischemic administration of
any MSC type, but mostly of BM-MSCs, remarkably
improves functional and structural recovery of the
ischemic limb.
MSCs Induce Neovascularization in Ischemic Muscles
To assess the angiogenic potential of MSCs, muscles were
double labeled with lectin, which stains endothelial and
mononuclear cells, and antibodies against a-smooth mus-
cle actin (a-SMA), which marks smooth muscle cells
(SMCs) surrounding arterial vessels (Figure 3A). Whereas
no significant difference in the number of lectin-positive
cells was detected, all three MSC populations stimulated a
massive formation of 10–100 mm arterioles (Figure 3B).
This effect was particularly pronounced in the case of
BM-MSCs.
Lead by recent literature supporting the paracrine ac-
tivity of MSCs (Gnecchi et al., 2012; Mirotsou et al.,
2011), we analyzed the mRNA levels of a series of mole-
cules involved in blood vessel formation and maturation
(Figure 3C). BM-MSCs were found to express particularly
abundant levels of factors required for vessel stabiliza-
tion, SMC migration, and matrix remodeling, such as
Tgf-b, Pdgf-b, and Mmp9. In addition, these cells also ex-
pressed high levels of Ccl5 and Sdf-1a, two chemokines
known to be involved in the recruitment and retention
of proangiogenic macrophages and MSCs themselves
(Abbott et al., 2004; Chen et al., 2008). Thus MSCs,
and in particular BM-MSCs, express a cocktail of soluble
factors able to enhance their retention in an autocrine
manner and also attract proangiogenic cells. To con-
firm the latter concept experimentally, we performed aell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authors 333
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Figure 1. Characterization of MSCs Isolated according to Three Different Procedures
(A) Schematic overview of MSCs isolation procedures.
(B) Counting of AT-MSCs, BM-MSCs, and iBM-MSCs for 4 consecutive days. Data (n = 3 biological replicates) are presented as mean ± SEM
(*p < 0.05).
(C) Crystal violet staining of MSCs showing colonies after 10 days of culture (upper panels) and a representative colony (lower panels).
Scale bar, 100 mm.
(D) Quantification of colonies formed after 10 days of cell culture. Data (n = 3 biological replicates) are presented as mean ± SEM.
(E) MSC immunophenotyping at passage 3. CD44 or CD105, red; DAPI, blue; scale bar, 50 mm.
(F) All MSCs exhibited a similar morphology and became positive for oil red (adipocytic differentiation; scale bar,
50 mm), alcian blue (chondrocytic differentiation; scale bar 50 mm), and alizarin red (osteocytic differentiation; scale bar,
80 mm).migration assay and found that BM-MSCs were the only
cell type able to attract murine SMCs (Figures 3D and
3E), similar to 10% fetal bovine serum (used as positive
control) and consistent with their abundant expression
of Pdgf-b at the mRNA and protein level (Figures 3C
and S2) (Gerthoffer, 2007). The ample production of
proangiogenic cytokines by the various MSCs suggested
that the same promigratory effect could be achieved by334 Stem Cell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Auththe delivery of their conditioned medium (CM). To
explore this possibility, we injected the medium har-
vested from the same number of AT-MSCs, iBM-MSCs,
and BM-MSCs (2 3 105) used in the previous experi-
ment, at days 1, 3, and 7 after surgery. This treatment
resulted in a clear trend toward improvement in all
the morphological and functional parameters analyzed
(Figure S3).ors
Figure 2. Morphological and Functional
Evaluation of the Therapeutic Effect
of MSCs
(A) CLI experimental flow chart. Mice were
injected with AT-MSCs, BM-MSCs, or iBM-
MSCs at passage 3–5 or medium (n = 10
animals per group).
(B) Limb function evaluation at days 2, 7,
and 21 after CLI according to the criteria
described in Table S2.
(C) Representative hematoxylin-eosin
staining of ischemic muscle from un-
treated and treated animals at day 21.
Scale bar represents 100 mm for lower
magnification and 10 mm for higher
magnification.
(D) Percentage of infiltrating cells at the
site of ischemia.
(E) Percentage of muscle affected by
ischemic damage.
(F) Quantification of central nuclei as a hallmark of muscle regeneration.
Data in (B) and (D)–(F) are expressed as mean ± SEM (n = 10 animals per group; *p < 0.05, **p < 0.01).BM-MSCs Stimulate Functional Neovascularization
but Are Not Incorporated in the Newly Formed
Vasculature
Functional muscle perfusion was evaluated by planar
scintigraphy (Figures 4 and S4). In control animals, a
large perfusion deficit was evident at day 1 and was still
present 2 weeks after ischemia. A statistically significant
improvement that was evident starting at day 7 after
injection was detected in the animals treated with BM-
MSCs (Figures 4B and 4C). A moderate recovery was
detected in iBM-MSC-treated animals at 1 week, while
AT-MSCs did not provide any benefit compared to con-
trols. Thus, BM-MSCs were the most effective cells in
inducing functional vascularization.
We then explored the possible mechanisms responsible
for the superior performance of BM-MSCs. We observed
that BM-MSCs and AT-MSCs resisted doxorubicin- or
hydrogen-peroxide-induced apoptosis more than iBM-
MSCs, as evaluated by caspase-3/7 activation and Annexin
V staining (Figures 4D and 4E). When analyzing their
persistence into ischemic muscles in vivo, we found
that the engraftment of BM-MSCs was significantly higher
at day 21 compared to the other twoMSC types (Figures 4F
and 4G). To investigate whether these cells directly
contributed to the formation of new vessels by transdiffer-
entiation, we evaluated the colocalization of 1,10-diocta-
decyl-3,3,30,30-tetramethylindocarbocyanine perchlorate
(DiI)-labeled MSCs with endothelial (CD31) and SMC
(a-SMA) markers. The complete lack of colocalization (Fig-
ures 4H and 4I) further supports a paracrine mechanism
responsible for their angiogenic properties.Stem CDISCUSSION
This study provides a comparison of the therapeutic
properties of three MSC populations isolated from two
different tissues (BM and AT) according to different purifi-
cation protocols. Our results show that (1) the three MSC
types acquire similar phenotypic and functional proper-
ties after the first passages, (2) any MSC type provides
therapeutic benefit after CLI, (3) BM-MSCs perform better
than the other types in preserving tissue viability and
inducing neovascularization, and (4) BM-MSCs do not
transdifferentiate in vivo into vascular structures but
persist longer and act in a paracrine manner to promote
vascular formation.
The first objective of this study was the definition of an
optimal protocol for MSC isolation. We intentionally
focused on BM and AT, as these are the most accessible tis-
sues for MSC recovery. Current protocols for AT-MSC isola-
tion are almost universally based on tissue digestion; for
the BM, instead, we selected the two most frequently
used methods, namely isolation based on MSC adhesive
properties (BM-MSCs) (Soleimani and Nadri, 2009) and
density gradient centrifugation, followed by immunode-
pletion (iBM-MSCs) (Sung et al., 2008).
Despite presenting a similar behavior in cell culture, the
three MSC types showed a different therapeutic potential
once injected in vivo in a CLI model, reducing necrosis
and inflammation and stimulating muscle regeneration,
although at a different extent. They also prompted the
formation of functional arterioles, in accordance with
previous reports (Cho et al., 2009; Iwase et al., 2005).ell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authors 335
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B Figure 3. MSC Treatment Effectively In-
duces Neovascularization in Ischemic
Muscles
(A) Representative immunostaining for
vascular structures at day 21. a-SMA, red;
lectin, green; DAPI, blue; scale bar, 50 mm.
(B) Number of a-SMA positive vessels. Data
(n = 10 animals per group) are expressed as
mean ± SEM (*p < 0.05, **p < 0.01).
(C) Quantification of mRNA levels of factors
involved in angiogenesis, vessel stabiliza-
tion, and remodeling (n = 3 biological rep-
licates). Expression of each gene was first
normalized over Gapdh and then over AT-
MSCs.
(D) Representative images of murine SMCs
migrated in response to the various MSCs.
SMCs were seeded on the upper chamber and
stained with DAPI after migration to the
bottom side of the filter. MSCs were seeded
in the lower chamber (n = 3 biological rep-
licates). Serum-free medium and serum-rich
medium were used as negative and positive
controls; scale bar, 100 mm.
(E) Quantification of SMCs migrated in
response to the various MSCs, expressed as
number of migrated cells per 1003 field.
Data in (B), (C), and (E) are expressed as
mean ± SEM (*p < 0.05, **p < 0.01).Interestingly, this was better accomplished by BM-MSCs,
which abundantly secreted soluble cytokines involved
in vessel remodeling and stabilization (such as PDGF-b)
and induced the migration of vascular SMCs. This contra-
dicts the findings of Kim et al., who attributed a higher
angiogenic and therapeutic potential to AT-MSCs in
comparison to MSCs of BM origin (Kim et al., 2007). A
few differences can explain this discrepancy. First, their
BM-MSCs were purified by density gradient centrifuga-
tion, while our results clearly indicate that the therapeutic
potential strictly depends on the isolation protocol.
Second, they transplanted human cells into nude mice,
which did not allow for the assessment of the immune-
modulatory action of MSCs.
Although multiple evidence points toward vascular
endothelial growth factor (Vegf) as the main angiogenic
cytokine secreted by MSCs (Kinnaird et al., 2004), we did
not observe significant differences in Vegf expression
among the three MSC types. Instead, the major differences336 Stem Cell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authoccurred in genes involved in SMC recruitment andmatrix
remodeling (Tgf-b, Pdgf-b, andMmp9), which are two essen-
tial events for the proper maturation of arterial vessels
(Zacchigna et al., 2008). Can this arteriogenic effect be
recapitulated by the delivery of the MSC supernatant?
Although not reaching statistical significance, probably
due to the relatively low number of animals analyzed, the
repeated injection of CM from the threeMSC types resulted
in a trend toward improvement, fully consistent with the
results observed upon cell transplantation. This supports
the conclusion that the MSC secretome could recapitulate
the effect of MSC injection (Ranganath et al., 2012), but
its effectiveness is most likely dampened by the short
half-life of its molecules. These results leave at least two
open questions. First, CM and MSC transplantation were
not performed on the same set of animals, and thus we
cannot exclude interanimal variability when comparing
the efficacy of the two treatments. Second, we did not
investigate whether the injection of higher CM amountsors
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Figure 4. MSCs Induce Functional Vascularization but Do Not Differentiate into Vascular Structures In Vivo
(A) Planar scintigraphy experimental flow chart (n = 8 animals per group).
(B) Representative images showing the regions of interest (yellow line) used to quantify muscle perfusion on the ischemic (I) and control
(C) limb at the indicated time points.
(C) Quantification of muscle perfusion, normalized over the perfusion measured at day 1.
(D) Level of caspase activation in MSCs exposed to doxorubicin, normalized over untreated cells (n = 9, 3 biological and 3 technical
replicates).
(E) Percentage of Annexin V+ cells after exposure to H2O2, normalized over untreated cells (n = 9, 3 biological and 3 technical replicates).
(F) Representative images of MSC engraftment at days 2 and 21. DiI-labeled MSCs, red; lectin, green; DAPI, blue; scale bar, 50 mm.
(G) Quantification of cell engraftment at the indicated time points (n = 6 animals per group).
(H) Representative images of DiI-labeled BM-MSCs (red) stained for CD31 (green). Nuclei are counterstained with DAPI (blue). Scale bar
represents 25 mm for lower magnification and 40 mm for higher magnification.
(I) Representative images of DiI-labeled BM-MSCs (red) stained for a-SMA (green). Nuclei are counterstained with DAPI (blue). Scale bars
as in (H).
Data in (C)–(E) and (G) are expressed as mean ± SEM (*p < 0.05, **p < 0.01).or the administration of more frequent doses would result
in a better outcome.
An additional reason for the higher therapeutic activity
of BM-MSCs could be related to the longer engraftment
and survival of the cells in vivo. In any case, it appears
important to remark that ourMSCs did not become immor-Stem Ctalized, as they underwent cellular senescence after passage
12 and we never observed formation of tumor masses dur-
ing long-term follow-up.
In conclusion, our findings indicate that BM-MSCs are
the most effective MSC type to improve perfusion and
functional recovery after hindlimb ischemia. In contrastell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authors 337
to initial studies supportingMSC plasticity (Quevedo et al.,
2009), these cells were not able to transdifferentiate into
either endothelial cells or SMCs while exerting their effect
through a paracrine mechanism.EXPERIMENTAL PROCEDURES
MSC Culture and In Vivo Experiments
MSCs were isolated from the ATor BM of C57/BL6 mice according
to three adapted protocols (Soleimani and Nadri, 2009; Sung et al.,
2008; Yamamoto et al., 2007). Cells (2 3 105) at passage 3–5 were
injected into the hindlimb of syngeneic mice the day following
resection of the femoral artery. Mice were monitored clinically
and by planar scintigraphy and sacrificed at day 21 for histological
analysis. Animal care and treatmentwere conducted in conformity
with institutional guidelines, in compliance with national and in-
ternational laws and policies (European Economic Community
Council Directive 86/609, OJL 358, December 12th, 1987, and
UE2010763), after institutional review board approval.
MSC Phenotypic Characterization
MSC-specific surface antigens were analyzed by flow cytometry
and immunofluorescence. Clonogenic potential was evaluated
upon staining with crystal violet. Differentiation was performed
using a dedicated kit from LifeLine Cell Technologies.
Histology and Immunofluorescence
Muscle sections were stained with hematoxylin-eosin to perform
morphometric analysis, with fluorescein isothiocyanate (FITC)-
conjugated lectin and anti-a-SMA antibodies to stain the vascula-
ture. Cells were labeled with DiI prior injection to track cell
engraftment.
Real-Time PCR
Total RNAwas extracted using TRIzol and reverse transcribed using
hexameric random primers. All the amplifications were performed
on a Bio-Rad real-time thermal cycler CFX96 using TaqMan probes
(Applied Biosystems).
Migration Assay
Murine SMC migration in response to MSC supernatant was per-
formed using 8 mm transwell supports (Costar, Corning).
Apoptosis Assay
MSC apoptosis was induced by hydrogen peroxide (H2O2) or doxo-
rubicin and quantified either by flow cytometry using the Annexin
V-FITC Apoptosis Detection Kit (Roche) or by using the Caspase-
Glo 3/7 Assay System (Promega).
Statistical Analysis
All in vitro experiments were repeated at least three times and
performed including at least three biological replicates. Data are
presented as mean and SEM. Comparison within groups was
analyzed by ANOVA (followed by Bonferroni post hoc analysis)
for the evaluation based on tissue sections. In the case of experi-338 Stem Cell Reports j Vol. 4 j 332–339 j March 10, 2015 j ª2015 The Authments entailing the follow-up of the same animals over multiple
time points, we used repeated-measures ANOVA to analyze statisti-
cal significance of the differences between groups over time. p <
0.05 was considered as statistically significant.
Additional details on the experimental procedures used in this
work are available in Supplemental Experimental Procedures.
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Procedures, four figures, and three tables and can be found
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